ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a prominent player in liquid biopsy technology focused on circulating tumor cell (CTC) diagnostics for research, drug development, and clinical oncology, has recently entered into a noteworthy agreement with Eisai Inc., a global pharmaceutical company.

In this collaboration, ANGLE will conduct a pilot study valued at US $250,000 for Eisai, leveraging its Portrait HER2 assay to evaluate the HER2 (human epidermal growth factor receptor 2) status of breast cancer patients in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. The success of the pilot study could potentially lead to multiple large-scale follow-up studies.

ANGLE's Portrait HER2 assay allows for the quantitative assessment of both HER2 protein expression (via immunofluorescence) and HER2/neu gene amplification (via fluorescence in situ hybridization), facilitating the identification of patients who may benefit from anti-HER2 ADC treatment. Notably, HER2-low breast cancer constitutes 55% of all breast cancer cases, and industry analysts project that the global HER2+ breast cancer ADC market will reach a significant US $3.3 billion annually by 2030. ANGLE's development of a quantitative HER2 assay addresses the need for accurate patient stratification throughout the treatment pathway, given that HER2 status can evolve over time.

Andrew Newland, CEO of ANGLE, expressed enthusiasm about the partnership, highlighting the growing importance of CTC biomarkers in clinical trials for monitoring genomic, transcriptomic, and proteomic changes over time. He emphasized the pivotal role of ANGLE's Portrait HER2 assay in evaluating HER2 status, especially in cases where traditional tissue biopsy at the metastatic site is either unsuccessful or not feasible. Newland believes that the success of this pilot study with Eisai could open up substantial opportunities for expansion in this aspect of ANGLE's business in the future.

 

Source: accesswire.com

Report Abuse